A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.
Status:
Terminated
Trial end date:
2019-01-16
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of mebendazole (ReposMBZ) in patient with
advanced gastrointestinal cancer or cancer of unknown origin. All patients will be given
ReposMBZ for 16 weeks continuous treatment, individually dosed based on the serum
concentration of mebendazole.